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Abstract
Background: The TSH stimulation test to confirm canine hypothyroidism is commonly performed using a
recombinant human TSH (rhTSH), as up to date, canine TSH is not yet commercially available. Limiting factors for
the use of rhTSH are its high costs and occasional difficulties in product availability. Less expensive bovine TSH
preparations (bTSH) purified from bovine pituitary glands are readily commercially available. The aim of this study
was to evaluate two different bTSH products as alternative to rhTSH using mass spectrometry.
Results: More than 50 proteins, including other pituitary hormones, bovine albumin, hemoglobin, and tissue
proteins were identified in the bTSH preparations. In contrast, rhTSH proved to be a highly pure product.
Significantly higher endotoxin levels could be detected in all bTSH products compared to the rhTSH.
Conclusions: Both bTSH products are crude mixtures and therefore not an acceptable alternative to rhTSH. Their
use should be discouraged to prevent unintended side effects.
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Background
The TSH stimulation test has long been recognized as an
accurate examination of thyroid function for the diagnosis
of hypothyroidism in dogs. Increases in T4 (thyroxin) after
the administration of exogenous TSH provide an assess-
ment of the functional reserve capacity of the thyroid
gland, and this helps discriminate true hypothyroidism
from other conditions with low T4 secretion [1,2]. Canine
TSH would be the ideal substance to perform the test, and
although canine recombinant TSH could successfully be
synthesized, it is not yet commercially available [3,4].
Therefore, the test is commonly performed using a recom-
binant human TSH (rhTSH) preparation [5-8]. Limiting
factors, however, are the high cost of rhTSH and the occa-
sional difficulties in obtaining the product. TSH purified
from bovine pituitary glands (bTSH), which is easily
commercially available, was widely used before rhTSH had
been introduced in veterinary medicine. Equivalent bio-
logical activity of a bTSH product and the rhTSH has been
shown in healthy beagle dogs [9]. However, in veterinary
but also human medicine side effects after the use of
bTSH were occasionally observed including allergic and
anaphylactoid reactions [10-14]. Although they were
assumed to result from impurities contained in the bTSH,
a detailed characterization of commercially available bTSH
to confirm this assumption has never been performed.
Mass spectrometry (MS) has been used to monitor pro-
tein purifications and to identify components in protein or
peptide mixtures [15-18]. MS has also been suggested as
an excellent analytical tool to establish key differences be-
tween recombinant proteins and their natural counter-
parts, especially when these products are intended for
clinical use [17]. To our knowledge, no MS studies have
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been conducted to describe the composition of commer-
cial bTSH products.
Important contaminants found in parenteral drugs are
endotoxins, also known as lipopolysaccharides (LPSs),
components of the outer membrane of gram-negative
bacteria. LPS in the blood circulation can lead to sys-
temic inflammation and endotoxin shock [19]. Possible
sources of endotoxins in drugs are chemicals, raw mate-
rials, or equipment used in the preparation and purifica-
tion of the products. The Limulus Amebocyte Lysate
(LAL) test is an officially accepted and very sensitive
method to test endotoxin levels. To date, there are no
published studies that compare the endotoxin content of
different TSH preparations.
Knowledge of the composition of bTSH and the identifi-
cation of potentially dangerous contaminants, e.g., endo-
toxins in this product are both prerequisites for veterinary
clinical use of bTSH.
Therefore, aim of this study was to characterize com-
mercially available purified bTSH (two different prod-
ucts) and rhTSH (one product) by MS. In addition, the
levels of endotoxin were measured in both preparations
by the Limulus endotoxin assay.
Results
Peptide and protein identification in bTSH
bTSH and rhTSH samples were separated by SDS-PAGE
before analyses by MS. Selected examples of Bis-Tris gels
after electrophoresis and Coomassie Blue staining of bTSH
and rhTSH-loaded gels are shown in Figure 1A (bTSH
product 1, Sigma Aldrich) and 1B (rhTSH), respectively.
In addition to bTSH, more than 50 other proteins were
identified in all bTSH samples, including other pituitary
hormones such as bovine prolactin, LH, arginine vasopres-
sin (AVP), proopiomelanocortin (POMC), GH, oxytocin-
neurophysin, and glycoprotein hormone alpha chain.
Moreover, bovine albumin, hemoglobin, and cytoskeleton
proteins were found in many of the tested samples. Inter-
estingly, major differences in the composition of albumin
were observed among the different lots of bTSH (bTSH
product 1, Sigma Aldrich), while the pituitary hormones
(prolactin, LH, AVP, glycoprotein hormone alpha
chain, and TSH) were not significantly different be-
tween the lots. A list of selected proteins of both prep-
arations is presented in Tables 1 and 2, respectively. A
complete summary of all identified proteins in bTSH
product 1 (three different lots) and 2 (one lot) are
presented as Additional file 1: Table S1 and Additional
file 2: Table S2, respectively; accession number and
number of assigned spectra are given.
Peptide and protein identification in rhTSH
In the rhTSH only TSH and several enzymes (e.g.,
caspase, galectin, serpin, calmodulin-like protein, and
glyceraldehyde-3-phosphate dehydrogenase species) could
be identified. In contrast to bTSH, the composition of
rhTSH was extremely consistent between the different lot
numbers.
A list of selected proteins from the two lot numbers of
rhTSH is shown in Table 3 and is given as the number of
assigned spectra. A complete summary of all identified
proteins in the rthTSH products is presented as Additional
file 3: Table S3; accession number and number of assigned
spectra are given.
Estimation of pituitary protein level
The number of detectable peptides of the identified pitu-
itary proteins was comparable. Therefore it was assumed
that the number of the detected spectra reflected the in-
dividual abundances of the proteins, which allowed an
estimation of the hormone quantities. Based on this as-
sumption, the most commonly occurring proteins in the
bTSH product 1 (Sigma Aldrich) were prolactin and LH
and although not statistically significant there was a
trend towards higher levels of both hormones compared
to the TSH (p = 0.1) and a trend towards lower GH
levels compared to those of TSH, LH and prolactin
Figure 1 Bis-Tris SDS PAGE gel of bTSH (product 1) and rhTSH
(each 70 μg/lane); after electrophoretic separation, protein
bands were detected by Coomassie Blue staining. The right lane
of each gel represents the molecular weight marker (Prestained
Protein Ladder; Page Ruler, Fermentas; Thermo Scientific, Glen
Burnie, MD, USA), the left lane of gel A and B, the bTSH and
rhTSH, respectively.
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(Figure 2). The rhTSH preparation had only minor
amounts of proteins other than TSH.
Contaminants such as keratin or trypsin, and proteins
that were detected in bTSH and in rhTSH were elimi-
nated from the analyses.
Measurement of LH and GH by ELISA
LH and GH were additionally measured by ELISA to
confirm the findings of the MS with respect to the
quantity of the hormone levels. The LH levels in the
bTSH (product 1, Sigma Aldrich) samples were signifi-
cantly higher compared to GH levels. Variations between
the three different bTSH lots were only minimal and not
statistically significant. Both, GH and LH levels in the
rhTSH preparations were undetectable (Table 4).
Endotoxin levels
Results of the LAL kinetic chromogenic assays of
bTSH and rhTSH preparations at different dilutions
are presented in Table 5. Endotoxin levels of all bTSH
preparations were significantly higher compared to
rhTSH. Further, large variations in endotoxin levels
were observed among the different lots of the bTSH
product 1 (Sigma Aldrich).
Discussion
Mass spectrometry analyses demonstrated that all bTSH
samples of two different products contained in addition
to TSH, more than 50 other proteins, including not only
other pituitary hormones (e.g. LH, prolactin, AVP,
POMC, and GH) but also bovine albumin, hemoglobin,
and several tissue proteins (e.g., collagen, superoxide
Table 1 Selected proteins identified in the bTSH product
1 (Thyrotropic hormone from bovine pituitary, Sigma
Aldrich; 3 lot numbers) by database search following
mass spectrometry
Identified proteins LOT
069 K1588
LOT
119 K1583
LOT
040 M1246
Prolactin 143 105 60
Lutropin subunit beta 100 84 86
Vasopressin-neurophysin2-
copeptin
85 87 61
Thyrotropin subunit beta 76 64 44
Glycoprotein hormones
alpha chain
57 73 75
Pro-opiomelanocortin 36 35 42
Serum albumin 25 1 0
Somatotropin 12 11 8
Beta-2-glycoprotein 1 5 2 0
Hemoglobin subunit beta 4 2 3
Oxytocin-neurophysin 1 4 2 2
Numbers of assigned spectra are given (corresponding to the numbers of the
acquired spectra per protein).
Table 2 Selected proteins identified in the bTSH product 2
(TSH, bovine pituitary, Calbiochem Merck; 1 lot number)
by database search following mass spectrometry
Identified proteins LOT
D00106386
Beta-2-glycoprotein 1 52
Serum albumin 51
Lactotransferrin 45
Hemoglobin subunit beta 32
Lutropin subunit beta 16
Glycoprotein hormones alpha chain 13
Thyrotropin subunit beta 13
Vasopressin-neurophysin 2-copeptin 7
Somatotropin 6
Pro-opiomelanocortin 4
Hemoglobin subunit alpha 3
Follitropin subunit beta 3
Numbers of assigned spectra are given (corresponding to the numbers of the
acquired spectra per protein).
Table 3 Selected proteins identified in the rhTSH
preparation (Thyrogen, Genzyme GmbH; 2 lot numbers)
by database search following mass spectrometry
Identified proteins LOT LOT
A8035H40 A8063H19
Thyrotropin subunit beta 116 126
Glycoprotein hormones alpha chain 25 26
Numbers of assigned spectra are given (corresponding to the numbers of the
acquired spectra per protein).
Figure 2 Numbers of assigned spectra of the hormones
detected in the bTSH (product 1, Sigma Aldrich). Each symbol
represents a lot number. The line represents the median of the 3
different lot numbers of each hormone. Thyroid stimulating
hormone (TSH), luteinizing hormone (LH), arginine vasopressin (AVP),
proopiomelanocortin (POMC), growth hormone (GH).
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dismutase, and cathepsin). In contrast, in the rhTSH
samples only TSH and a low number of enzymes used
for its production were detected.
Recombinantly produced proteins usually contain only
the protein or peptide coded by the target gene, and some
minor enzymes used in the commercial production
process. rhTSH (Thyrogen) is produced in genetically
engineered cell lines (Chinese hamster ovary cells- CHO)
and is highly purified by a combination of ion exchange
and dye affinity chromatography [20] (Genzyme Corpor-
ation, www.genzyme.com).
In contrast to rhTSH, the bTSH products are purified
proteins, prepared from the entire bovine pituitary
gland. Depending on the purification procedure, it may
be difficult to obtain a real pure product, particularly if
proteins with high similarities to the target protein (in
our case TSH) are present. It was therefore not surpris-
ing that other pituitary hormones were found in the
various bTSH lots. Major cell types of the anterior pituit-
ary are somatotropic cells, constituting approximately 50%
of the cell population, followed by lactotropic (10-25%),
corticotropic (10-20%), gonadotropic (10%), and thyrotro-
pic cells (10%) [21].
Based on the high proportion of somatotropic cells in
a pituitary mixture, a higher quantity of growth hor-
mone would be expected if the protein purification
method was non-specific. However, the proportion of
GH in bTSH as determined by MS analyses and ELISA
was low, confirming that the TSH purification was to
some extent specific.
TSH belongs to the glycoprotein hormone family that
includes FSH, hCG and LH; they are heterodimeric pro-
teins and consist of a common α-subunit (or α-chain)
and a unique β-subunit, which confers biological specifi-
city to each hormone. Due to the very high homology
between TSH and LH, separation of the two hormones
is difficult and necessitates extensive purification proce-
dures [22-24], which in turn is laborious and expensive.
Based on our results showing a rather high proportion
of LH (demonstrated by MS and ELISA), it can be as-
sumed that such a special purfication procedure has not
been applied in the case of our bTSH.
In a previous study, we found that the administration
of 75 μg rhTSH to healthy beagle dogs resulted in stimu-
lation of T4 similar to that caused by administration of
500 μg bTSH (product 1) [9]. Based on the current
results, the more than six times higher dose of bTSH
required to elicit the same effect as rhTSH can be
explained by the high content of contaminating proteins
in the bTSH lots. As mentioned above, the amounts of
GH in the bTSH products were low, which led us to as-
sume that at least some specific purification procedure
was used; the more surprising was the finding of the
highly variable amounts of bovine albumin that we could
detect. Before rhTSH was available, bTSH given to
human patients caused allergic reactions in up to 43% of
the cases; some patients required emergency treatment
[12-14]. Contaminating proteins such as albumin or glob-
ulins and antibodies against these proteins were suspected
to be a likely cause and most side effects were observed
after repeated injections of bTSH [12,13]. In veterinary
medicine, side effects after the use of bTSH include aller-
gic and anaphylactoid reactions [10,11]. Although these
reactions were assumed to result from impurities
contained in the bTSH, a detailed characterization to con-
firm this assumption has not been performed. If foreign
albumin is administered, species differences in albumin
can lead to anaphylactic and immunologic reactions. This
has been shown both in human patients and in dogs
[25-30]. Clinical symptoms in dogs receiving non-canine
albumin ranged from edema (facial, distal limbs), urticaria,
vomiting, and diarrhea to severe shock-like reactions
(hypotension, collapse). Some of these symptoms have
also been observed in dogs receiving bTSH, making
adverse reactions to albumin contained in bTSH a
likely factor. In one veterinary study, reactions had
only been observed after repeated administration of
bTSH. The authors hypothesized that these reactions
were the result of hypersensitization [11]. Clearly, to
avoid hypersensitization, a canine TSH would be the
most appropriate substance for performing the TSH
stimulating test in dogs. However, to our knowledge,
Table 4 Bovine luteinizing hormone (LH) and bovine
growth hormone (GH) concentrations in bTSH and rhTSH
preparations as determined by ELISA
TSH product LOT LH (μg/ml) GH (μg/ml)
bTSH 040 M1246 34.9 2.59
37.4 2.29
119 K1583 35.4 2.97
34.5 2.75
rhTSH A8063H19 < 1.2 ng/ml < 0.8 ng/ml
Table 5 Endotoxin concentrations in two bTSH products
(Sigma Aldrich, 3 lot numbers; Calbiochem Merck 1 lot
number) and rhTSH (2 lot numbers) as determined by
Limulus amebocyte lysate (LAL) kinetic chromogenic
assay
Sample LOT Endotoxin/ml Endotoxin/mg
bTSH 069 K1588 434 EU/ml 80.4 EU/mg
(Sigma Aldrich) 119 K1583 158.4 EU/ml 29.3 EU/mg
040 M1246 133.6 EU/ml 24.7 EU/mg
bTSH D00106386 622 EU/ml 12.4 EU/mg
(Calbiochem Merck)
rhTSH A8035H40 0.15 EU/ml 0.14 EU/mg
(Genzyme GmbH) A8063H19 <0.05 EU/ml <0.04 EU/mg
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purified canine TSH is not commercially available in
sufficient amounts and although recombinant canine
TSH could successfully be synthesized, it is not yet on
the market [3,4].
However, in one report, two fatal outcomes were
described after a single administration of bTSH to dogs
that had no prior exposure to bTSH [10]. A possible ex-
planation in these cases, in which a hypersensitization
can be excluded, would be the high endotoxin concen-
tration in some bTSH lots. Based on the LAL assay, the
endotoxin concentration in bTSH was up to 500 times
higher than that measured in rhTSH (434 and 0.27 EU/mL,
respectively). Endotoxins in the blood circulation can lead
to systemic inflammation and endotoxin shock with severe
cardiovascular disturbances, multi-organ failure, and pos-
sible fatal outcome [19]. The highly variable endotoxin
content in different lots makes adverse reactions unpre-
dictable, and hence, the administration of bTSH to dogs is
risky. Based on the high level of purity and the lack or
minimal amount of endotoxin content, adverse reactions
to rhTSH are unlikely. Therefore, compared to bTSH,
rhTSH can be regarded as a much safer product. This
assumption is supported by the finding that thus far, no
adverse reactions in dogs have been observed even after
the repeated administration of rhTSH [5,6,9]. In selected
dogs in which hypothyroidism had been suspected, we re-
peated the TSH stimulation test three times using rhTSH.
Even though the third test was performed within 12 to
24 months after the first stimulation, no dogs had adverse
reactions after the rhTSH administration [6].
The bTSH is commonly used also for in vitro experi-
ments to test the influence of TSH [31-34]. With our data,
we could show that other pituitary hormones, albumin,
endotoxins and an extensive list of contaminating proteins
(e.g., collagen, hemoglobin, superoxide dismutase, and ca-
thepsin) are constituents in two different bTSH products.
The effects of these impurities are rarely if ever considered
in interpretations of the results from these cell culture
experiments. However, in the light of our findings, the
rhTSH should be preferred for in vitro usage if the sole
effect of TSH has to be tested.
Conclusion
The results of the present study show that rhTSH is a very
pure product with minimal to no amounts of endotoxin,
whereas bTSH is a crude mixture of proteins with a high
level of endotoxin. Both, contaminating proteins like bo-
vine albumin and the high endotoxin content in the bTSH
can potentially lead to adverse reactions, which have been
observed in the past, not only in humans, but also in
veterinary medicine [10-14]. The highly variable and lot-
dependent composition of the bTSH makes adverse reac-
tions unpredictable. Consequently, although less expensive
and easily available, bTSH cannot be regarded as an
alternative to the more expensive rhTSH, and its use
should be discouraged to prevent unintended side effects
in vitro and in vivo.
Methods
Sample preparation
Two different bovine TSH products (Thyrotropic hor-
mone from bovine pituitary; product 1 Sigma Aldrich,
Buchs, Switzerland and product 2 Calbiochem, Merck
Chemicals, Lucerne, Switzerland) and rhTSH (Thyrogen,
Genzyme GmbH, Baar, Switzerland) were analyzed. All
TSH products were dissolved in aqua ad iniectabilia
(Fresenius Kabi AG, Stans, Switzerland), and 70 μg total
protein of each TSH sample were loaded separately onto
a 12%- Bis-Tris gel (NuPage Novex Bis-Tris Mini Gel,
Invitrogen AG, Basel, Switzerland). After separation, the
gels were stained with colloidal Coomassie Blue
(RotiBlue, Roth, Karlsruhe, Germany) and the stained
gel lanes were excised, digested in-gel, and finally
dissolved in 3% acetonitrile/0.1% formic acid for MS
analyses as previously described [35].
Mass spectrometry analyses
Analyses were performed with an LTQ-FT-ICR Ultra mass
spectrometer (Thermo Fisher Scientific, Pittsburgh, PA,
USA) equipped with an Eksigent-Nano-high performance
liquid chromatography system (Eksigent Technologies,
Dublin, CA, USA) as described by Moretti et al. [35]. An
inclusion list was used containing the m/z values of all
doubly and triply charged tryptic peptides from human
(P01222) and bovine (P01223) TSH.
Peptide and protein identification (data analyses)
The MS data were analyzed and peptides identified with
Mascot (Version 2.3.0, Matrix Science) using the Swiss-
Prot database (release date, 05.Oct10; 521016 sequence
entries). The peptide tolerance was set to ± 5 ppm, the
MS/MS tolerance to ± 0.6 Da, and carbamidomethylation
of cysteine was specified as a fixed modification.
Determination of bovine growth hormone concentration
The concentration of bovine growth hormone (GH) was
measured in duplicate by an Enzyme-linked Immuno-
sorbant Assay (ELISA) using a GH antibody (10 mg/mL,
100 μL total volume, 1: 200 000 dilution, anti-ovine GH-3,
Lot# AFP0802210Rb) obtained from Dr. Parlow [National
Hormone & Peptide Program (NHPP) of the National
Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health, Bethesda, MD,
USA]. The assay was performed as previously described,
but with the following modifications [36,37]. The anti-ovine
GH antibody was distributed into all wells of microtiter
plates, which had been coated with anti-rabbit-globulin
antiserum, and incubated for 24 h at room temperature.
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After decanting the supernatants, 15 μL of different
concentrations of GH standard (0.8–100 ng/mL, NIDDK-
bGH, AFP-10325C) diluted in assay buffer (7.1 g/L
Na2HPO4, 1.1 g/L KH2PO4, 1.2 g/L NaCl, and 1.8 g/L
EDTA, pH 7.5; containing 1% chicken serum; 100 μg/well),
and samples were added and incubated for 24 h. After
incubation, the supernatants were discarded and biotin-
labeled GH was added and incubated for 3 h at room
temperature. Finally, the substrate was added (40 min at
37°C), and after stopping, the reaction, the optical density
was measured at 450 nm. Only concentrations in the lin-
ear range of the standard curve were evaluated. Therefore,
lower and upper detection limit for undiluted samples
were 2.0 and 50.0 ng/mL, respectively (working range).
The EIA method was validated for protein extraction sam-
ples by analyzing linearity of dilution and intra-assay coef-
ficient of variation (CV) using the respective TSH diluted
in GH assay buffer. The signal linearity of dilution was
81–96%, the intra-assay CV was 15.1%, and the 50% bind-
ing of this assay system was 6.2 ng/mL. Protein samples
were diluted 1:10 in water and additionally 1:20 in peptide
buffer.
Determination of bovine luteinizing hormone concentration
Bovine luteinizing hormone (LH) concentration was mea-
sured in duplicate using a solid phase two-site enzyme
immunoassay kit (LH Detect, INRA, Tours, France). The
immunoassay was validated for purified protein samples
by analyzing linearity of dilution, and the intra-assay CV.
The assay sensitivity was 1 ng/mL, and the intra-assay CV
was 9.6%. Linearity of dilution was 82–102%. Protein for
LH detection was diluted in water at 1:100 and addition-
ally 1:100 in assay buffer. The standard curve ranged from
1.2 - 40 ng/mL.
Endotoxin assay
Endotoxin levels were measured using a Limulus amebo-
cyte lysate (LAL) kinetic chromogenic assay (Pyrogent
LAL Chromogenic Assay, Lonza, Verviers, Belgium). The
test is based on the measurement of the chromophore re-
leased from a suitable chromogenic peptide by the reac-
tion of endotoxins with the lysate. Bacterial endotoxin was
measured with upper and lower detection limits of 0.05
and 50 Endotoxin units (EU)/mL, respectively. The sample
was mixed with the LAL/substrate reagent, placed in an
incubating plate reader, and monitored over time for the
appearance of a yellow color, according to the instructions
of the manufacturer. The same TSH lots were used for
endotoxin assays and mass spectrometry. Results are given
in both EU/mL and EU/mg.
Statistical analyses
Statistical support was provided by the biostatistical staff
of the FGCZ. MS data were analyzed using Scaffold 3
(Proteome Software, Portland, OR, USA) The threshold
for positive identification of a given protein was set to at
least two peptides with a peptide probability of 95% or
better. The minimal sequence coverage was set to a mini-
mum of 10%. Data were further analyzed using non-
parametric statistical methods (SPSS, Statistical Package
for the Social Science, Software Packets for Windows, Ver-
sion 18 and GraphPad PRISMW for Windows, Version 5.0)
Kruskal-Wallis, Wilcoxon and Dunn’s multiple compari-
sons test were used. The Mann–Whitney-U-Test was used
to determine differences between two groups (hormones,
endotoxins). Values of p < 0.05 were considered statisti-
cally significant.
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Additional file 1: Table S1. (Complete, including accession number).
Complete list of the proteins identified in the bTSH product 1
(Thyrotropic hormone from bovine pituitary, Sigma Aldrich; 3 lot
numbers) by database search following mass spectrometry. Numbers of
assigned spectra are given and the minimal sequence coverage was set
to a minimum of 10%. Contaminations like keratin or trypsin, which were
registered in bTSH as well as in rhTSH were excluded from analyses.
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Complete list of identified proteins in the bTSH product 2 (TSH, bovine
pituitary, Calbiochem Merck; 1 lot number) by database search following
mass spectrometry. Numbers of assigned spectra are given and the
minimal sequence coverage was set to a minimum of 10%.
Contaminations like keratin or trypsin, which were registered in bTSH as
well as in rhTSH were excluded from analyses.
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Complete list of identified proteins in the rhTSH preparation (Thyrogen,
Genzyme GmbH; 2 lot numbers) by database search following mass
spectrometry. Numbers of assigned spectra are given and the minimal
sequence coverage was set to a minimum of 10%. Contaminations like
keratin or trypsin, which were detected in bTSH as well as in rhTSH were
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